Professional Documents
Culture Documents
Introduction To Molecular Dynamics Simulations
Introduction To Molecular Dynamics Simulations
Roland H. Stote Institut de Chimie LC3-UMR 7177 Universit Louis Pasteur Strasbourg France
1EA5
Title Native Acetylcholinesterase (E.C. 3.1.1.7) From Torpedo Californica At 1.8A Resolution Classification Cholinesterase Compound Mol_Id: 1; Molecule: Acetylcholinesterase; Chain: A; Ec: 3.1.1.7 Exp. Method X-ray Diffraction
Macromolecules in motion
Local motions
(0.01 5 , 10-15 10-1 s) Atomic Fluctuations Sidechain motions Loop motions (1 10 , 10-9 1 s) Helix motions Domain motions Subunit motions (> 5 , 10-7 104 s) helix-coil Transitions Dissociation/Association Folding and unfolding
Energy Minimization
"E a # b # "E b # c # "E c ### "E MIN $ 0 # fin
c b
Classical Dynamics
Newtons Equations of motion
dvi d 2ri Fi = mi ! ai = mi ! = m! 2 dt dt
Fi = !"i E
Position, speed and acceleration are functions of time ri(t); vi(t); ai(t) The force is related to the acceleration and, in turn, to the potential energy Integration of the equations of motion => initial structure : ri(t=0); initial distribution of velocities: vi(t=0)
dvi d 2ri Fi = mi ! ai = mi ! = m! 2 dt dt
v = at + v0
a=
dv dt
a=
dv dt
v(t) = at + v0
v(t) = dx(t) dt
Position: The trajectory x(t) obtained by integration taking into account the initial positions and velocities (x0 et v0)
t2 x(t) = v ! t + x0 = a ! + v0t + x0 2
Balistic trajectory
Initial conditions are x(0) = z(0) = 0 vx (0) = vo cos vz (0) = vo sin In the x direction ax = 0 vx (t) = vo cos x(t) = vo cos t
Z
V0 X
In the z direction, one has to take into account gravity az = g vz (t) = vo sin - gt z(t)= vo sin t g t2 /2 z = ax -b x2 : the trajectory in the (x,z) plane is parabolic
Potential Energy
E(R) = 1 2 1 2 Kb ( b " b0 ) + ! K# (# " # 0 ) + ! K$ (1 + cos(n$ " % )) 1, 2 pairs 2 angles 2 dihedrals
Numerical Integration
Taylor series development
Potential Energy
E(RN ) =
1,2 pairs 2
1 2 K# (# " # 0 ) +
dihedrals
! K$ (1 + cos(n$ " % ))
Trajectory of a macromolecule
Initial positions x0
PDB le Xray NMR Model
Initial velocities v0
3 m v2 NkT = ! i i 2 2 i
Acceleration
Calculated from the force, that is, from the derivative of the potential energy.
a=!
1 dE m dr
3 m v2 NkT = ! i i 2 2 i
Molecular Dynamics Simulation programs AMBER CHARMM NAMD POLY-MD etc Potential energy function parameter les contain the numerical constants needed to evaluate forces and energies
http://www.pharmacy.umaryland.edu/faculty/amackere/research.html
10
Molecular Dynamics
Calculation of forces Displacement t=t New set of coordinates
Practical Aspects
Choice of integration timestep t
> As long as possible compatible with a correct numerical integration > 1 to 2 fs (10-15 s)
11
E(R) =
! r
Kb ( b " b0 ) +
angles
1 ! 2 K (# " # )
#
0
dihedrals
K$ (1 + cos(n$ " % ))
Truncation
Switch
Bring the potential to zero between ron and roff. The potential is not modied for r < ron and equals zero for r > roff
Shift
Modify the potential over the entire range of distances in order to bring the potential to zero for r > rcut
12
Treatment of solvent
Implicit: The macromolecule interacts only with itself, but the electrostatic interactions are modied to account for the solvent
E elec (r ) = A
qi q j
!r
Treatment of solvent
Explicit representation The macromolecule is surrounded by solvent molecules (water, ions) with which the macromolecule interacts. Specic nonbond interactions are calculated
13
Boundary Conditions
Solvation sphere: nite system Around the entire macromolecule Around the active site
14
Temperature Fators
Radius of gyration
Treatment of solvent
implicit: choice of dielectric constant Implicit: advanced treatment of solvent: Generalized Born, ACE, EEF1 explicit: solvation protocol
15
16
Acetylcholinesterase
Acetylcholinesterase (AChE) is an enzyme that hydrolyzes ACh to acetate and choline to inactivate the neurotransmitter A very fast enzyme, approaching diffusion controlled. Inhibitors are utilized in the treatment of various neurological diseases, including Alzheimers disease. Organophosphorus compounds serve as potent insecticides by selectively inhibiting insect AChE.
17
1EA5
Title Native Acetylcholinesterase (E.C. 3.1.1.7) From Torpedo Californica At 1.8A Resolution Classification Cholinesterase Compound Mol_Id: 1; Molecule: Acetylcholinesterase; Chain: A; Ec: 3.1.1.7 Exp. Method X-ray Diffraction
18
Biophysical Journal Volume 81 715-724 (2001) Acc. Chem. Research 35 332-340 (2002)
19
20
Effect of the His44Ala mutation on the Nucleocapsid protein from the HIV virus - NC(35-50) Working at the interface of theory and experiment
21
The life cycle of the HIV-1 retrovirus and the multiple roles of the nucleocapsid protein
NC
NC
NC
NC
22
Structural determinants for the specicity of NC for DNA The structure of the mutant His44Ala:NC(35-50):an NMR, MM and FL study
Answer the questions left unanswered by experiment How does mutant protein bind zinc ion? If folded, why is the activity diminished? Can simulations can predict the structural effects of point mutations?
23
From NMR
From MD
angular S
1.2
rmsd ()
0.8 0.7 0.6
0.8
0.6
0.4
0.2
0.1 0 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50
residue number
1991
Free
Complex
24
0.5
-0.5
-1
-1.5
-2
Zinc binding by the mutant protein Reorientation of mainchain carbonyl oxygens stabilizes the ion zinc. In more unfolded protein, water molecules move in to form hydrogen bonds
25
MET 46
TRP 37
Decomposition of the binding free energy by amino acid for the native protein
Amino acids that contribute signicantly to DNA binding are those most affected by the mutation
26
Conclusions
Since molecules are dynamic, experimental structures alone can not give the entire picture. An interdisciplinary approach is required. Molecular simulations are a necessary complement to the experimental studies.
Computational Chemistry
http://www.ch.embnet.org/MD_tutorial/
27
Acknowledgements
Herv Muller Elyette Martin
Prof. Bruno Kieffer (ESBS/IGBMC, Illkirch) Dr. Esther Kellenberger (ULP, Illkirch) Marc-Olivier Sercki (ESBS, Illkirch) Prof. Yves Mly (ULP, Illkirch) Dr. Elisa Bombarda (ULP, Illkirch) Prof. Bernard Roques (INSERM/CNRS, Paris)
28